FAST-EU: Accelerating Clinical Trial Approvals Across Europe

The European clinical trial landscape continues to evolve, with regulators seeking new ways to streamline development pathways while maintaining rigorous oversight. One of the latest initiatives aimed at improving efficiency is FAST-EU (Facilitating and Accelerating Strategic Clinical Trials in the European Union/European Economic Area), a pilot programme operating within the framework of the Clinical Trials Regulation (CTR). 

A New Route for Faster Clinical Trial Assessment 

FAST-EU is designed to accelerate the assessment of multinational clinical trial applications across participating EU and EEA Member States. The programme’s defining feature is a maximum assessment timeline of 70 calendar days from submission to final outcome, including time allocated for sponsor responses. 

The initiative is currently operating as a voluntary one-year pilot and accepts a limited number of applications each month. Sponsors interested in participating must submit an expression of interest in advance. 

Since its launch, the pilot has generated significant interest, with 68 expressions of interest received and 15 clinical trials selected for assessment. Participation is broad, with almost all EU Member States involved in the scheme. Importantly, the legal rights and obligations of sponsors remain unchanged under the programme. 

Why FAST-EU Matters 

Lengthy and complex approval processes can be a significant challenge for sponsors conducting multinational clinical trials. By reducing assessment timelines and promoting coordinated review across Member States, FAST-EU represents another step towards a more efficient European clinical research environment. 

For sponsors developing innovative therapies, particularly those operating in competitive therapeutic areas, accelerated regulatory timelines can translate into faster study initiation, more predictable development planning, and earlier access to critical clinical data. 

The initiative also reflects a broader regulatory trend across global markets: finding ways to maintain high scientific and ethical standards while reducing unnecessary administrative delays. 

Opportunities and Considerations 

While the potential benefits of FAST-EU are clear, sponsors should recognise that participation is currently limited. With only a small number of trials selected each month, early planning and strategic preparation are essential. 

Sponsors should also carefully evaluate whether their development programmes align with the objectives of the pilot and ensure that submission packages are of sufficient quality to support accelerated review timelines. 

As with any expedited pathway, the ability to respond rapidly and effectively to regulatory questions may be critical to maintaining momentum throughout the assessment process. If FAST-EU internal timelines cannot be met, then the procedure would continue under the applicable legal CTR timelines 

Preparing for Success 

FAST-EU may offer valuable opportunities for sponsors seeking to accelerate clinical development in Europe, but success will depend on proactive planning, robust regulatory strategy, and well-prepared submissions. 

Understanding eligibility requirements, managing timelines effectively, and coordinating regulatory activities across multiple jurisdictions can help maximise the benefits of the programme while minimising potential delays. 

As the pilot progresses, its outcomes are likely to provide important insights into the future direction of clinical trial assessment in Europe. 

How tranScrip Can Help 

Whether you are considering FAST-EU participation or navigating broader clinical development challenges, tranScrip’s regulatory and clinical experts can provide strategic guidance throughout the development lifecycle. Our team supports sponsors in designing efficient regulatory pathways, preparing high-quality submissions, and accelerating development programmes to bring innovative medicines to patients across Europe and beyond. Speak to one of our experts:  Contact tranScrip | A Specialist Pharmaceutical Consultancy